From: usamraa at aibs.org (AIBS)
The U.S. Army Medical Research and Acquisition Activity at Ft. Detrick,
Maryland has recently placed three announcements in Commerce Business
Daily (CBD) regarding Persian Gulf War Illness research. The most recent
announcement, posted on 31 January 1997, amends two earlier announcements
posted on 14 January 1997 and 10 December 1996.
The 31 January 1997 CBD announcement modifies the amount of funds
available for research as well as the proposal due dates. All three CBD
announcements are included. Note that the 31 January 1997 CBD
announcement takes precedence over the earlier two announcements.
____________________
COMMERCE BUSINESS DAILY ISSUE OF JANUARY 31, 1997
PSA#1773
DIRECTOR, USAMRAA,
820 CHANDLER ST, FORT DETRICK MD 21702-5014
PERSIAN GULF WAR ILLNESS RESEARCH
SOL CBD700-0000-0001
POC Contracting Officer Craig D. Lebo
(301) 619-2036 (Site Code DAMD17)
The U.S. Army Medical Research and Acquisition Activity previously
announced in the Commerce Business Daily the interest in obtaining
proposals for the conduct of research in the area of Persian Gulf War
Illnesses (see CBD Issue PSA #1738, dated December 10, 1996 and CBD Issue
PSA #1761, dated January 14, 1997).
These previous Department of Defense announcements, which solicited
research proposals on four topics related to Persian Gulf War Illnesses
are modified as indicated below with due dates as follows:
(1) Determine the feasibility of epidemiological studies in human
subjects, including those thought to be near Kamisiyah, Iraq during the
first two weeks of March, 1991 or (2) Conduct animal studies, designed to
assess the possible long-term or delayed clinical effects of low level or
subclinical exposures to chemical warfare agents. Additional details
concerning these two topics are provided in the first announcement (CBD
Issue PSA #1738, dated December 10, 1996). There is approximately $2.0M
available for this effort and proposals will be considered from federal
and nonfederal agencies. Proposals must be received NLT 4:00 p.m. EST, 19
February 1997.
(3) Investigation of causal relationships between illnesses and symptoms
among Gulf War veterans and possible exposures to hazardous material;
chemical warfare agents; stress; potentially hazardous combinations of
inoculations (i.e., anthrax and botulinum toxin) and investigational new
drugs (i.e., pyridostigmine bromide) during military service in the
Southwest Asia theater of operations during the Persian Gulf War.
Approximately $9.5M is available only to principal investigators and
institutions independent of the Federal Government in accordance with the
provisions of the Byrd Amendment. Proposals must be received NLT 4:00 p.m.
EST, 11 March 1997.
(4) Studies of historical war syndromes, including investigation of
factors which create a confluence of cognitive, emotional and physical
factors to produce chronic, non-specific symptoms and physiological
outcomes (e.g., neurologic, immunologic and endocrine responses). There is
approximately $5M available for proposals from federal and nonfederal
agencies. Proposals must be received NLT 4:00 p.m. EST, 30 April 1997.
Large scale epidemiological studies must include provisions for scientific
and public advisory committees as recommended by the Presidential Advisory
Committee on Gulf War Veterans' Illnesses and Persian Gulf Veterans
Coordinating Board.
Research proposals are customarily in two to four year durations.
Proposals should be submitted in accordance with Broad Agency Announcement
95-1 which is available on the internet. The web site is
http://www.usamraa.army.mil
Send proposals to: Commander, U.S. Army Medical Research and Materiel
Command, ATTN: MCMR-AAA, Fort Detrick, MD
NOTE: This CBD announcement can be downloaded at:
http://www.ld.com/cbd/archive/1997/01(January)/31-Jan-1997/Asol019.htm
____________________
COMMERCE BUSINESS DAILY ISSUE OF JANUARY 14,1997 PSA#1761
DIRECTOR, USAMRAA, 820 CHANDLER ST, FORT DETRICK MD 21702-5014
PERSIAN GULF WAR ILLNESS RESEARCH
SOL 074&&&-9701-0003
POC Contracting Officer Craig D. Lebo
(301) 619-2036 (Site Code DAMD17)
The U.S. Army Medical Research Acquisition Activity previously announced
in the Commerce Business the interest in obtaining proposals for the
conduct of research in the area of Persian Gulf War Illness. (see CBD
Issue PSA #1738, dated December 10, 1996).
This previous Department of Defense announcement, which solicited research
proposals on Persian Gulf War Illnesses research, is expanded to include
two additional topics:
(1) causal relationships between illnesses and symptoms among Gulf War
veterans ad possible exposures to hazardous material; chemical warfare
agents; stress; potentially hazardous combinations of inoculations (ie,
anthrax and botulinum toxin) and investigational new drugs (ie,
pyridostigmine bromide) during military service in the Southwest Asia
theater of operations during the Persian Gulf War, and (2) studies of
historical war syndromes, including investigation of factors which create
a confluence of cognitive, emotional and physical factors to produce
chronic, non-specific symptoms and physiological outcomes (e.g.,
neurologic, immunologic and endocrine responses).
Large scale epidemiological studies must include provisions for scientific
and public advisory committees as recommended by the Presidential Advisory
Committee on Gulf War Veterans' Illnesses and Persian Gulf Veterans
Coordinating Board. Approximately $9.5 M in additional funding is
available only to principal investigators and institutions independent of
the Federal Government in accordance with the provisions of the Byrd
Amendment.
Proposals should be submitted in accordance with broad Agency Announcement
95-1 and received NLT 19 February 1997.
NOTE: This CBD announcement can be downloaded at
http://www.ld.com/cbd/archive/1997/01(January)/14-Jan-1997/Asol006.htm
___________________
COMMERCE BUSINESS DAILY ISSUE OF DECEMBER 10,1996 PSA#1738
DIRECTOR, USAMRAA, MCMR-AAA,
BLDG 820, FORT DETRICK, FREDERICK MD 21702-5014
PRE-FORMULATION STUDIES AND FORMULATION OF INVESTIGATIONAL NEW DRUG
SOL DAMD17-97-R-0001
DUE 123196
POC Contract Specialist Nancy G. Mohler
(301) 619-7424 (301) 619-2937 FAX
Contracting Officer Patricia M. McAllister
(301) 619-7360 (Site Code DAMD17)
The U.S. Army Medical Research and Materiel Command (USAMRMC) has as one
of its responsibilities the development of new drugs to protect or treat
soldiers confronted with threats on the modern battlefield or exposed to
endemic diseases during deployment. Preformulation studies and formulation
development are needed in the early stage of drug development. During the
clinical study phases, production and delivery of clinical batches of
formulated products are required.
A contractor is needed (1) to determine the essential physical and
chemical properties of candidate drugs with the ultimate goal of designing
an optimal dosage form or drug delivery system, (2) to design, formulate,
test, and produce clinical batches of solid oral, parenteral, or other
dosage forms to support phase I, II and III clinical trials. All studies
and productions must be in compliance with the current Good Manufacturing
Practice (cGMP) Regulations and be performed in an FDA-licensed facility.
The contractor should be sufficiently flexible so as to be able to study
more than one candidate drug and drug formulations simultaneously. The
contractor must also be able to respond rapidly to changing priorities.
The Army expects to award a 5 year contract. RFP DAMD17-97-R-0001 to be
issued on/or about 06 January 1997. Only written requests will be
accepted. Proposals will be due approximately 45 days after issue date.
This CBD announcement amends and replaces the original announcement issued
18 November 1996. Contractors who have requested copies of the RFP as a
result of the previous announcement need not resubmit their requests.
NOTE: This CBD announcement can be downloaded at
http://www.ld.com/cbd/archive/1996/12(December)/10-Dec-1996/Asol007.htm
